Skip to main content
Jonathan Bernstein, MD, Allergy & Immunology, Cincinnati, OH

JonathanAbramBernsteinMD

Allergy & Immunology Cincinnati, OH

Professor of Medicine, University Cincinnati

Dr. Bernstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bernstein's full profile

Already have an account?

  • Office

    4665 E Galbraith Rd
    Fl 2
    Cincinnati, OH 45236
    Phone+1 513-931-0775
    Fax+1 513-931-0779

Summary

  • Dr. Jonathan Bernstein is an allergist/immunologist in Cincinnati, OH and is Professor of Clinical Medicine at the University of Cincinnati College of Medicine Department of Internal Medicine, Division of Internal Medicine Division of Rheumatology, Allergy and Immunology and partner of Bernstein Allergy Grouo and Bernstein Clinical Research Center. He received his medical degree from University of Cincinnati College of Medicine completed his IM residency at the Cleveland Clinic and Allergy fellowship at Northwestern University. He has been in practice 32 years. He is experienced in asthma, rhinitis., hereditary angioedema, mast cell disorders, allergic skin disorders including urticaria, progesterone hypersensitivity and atopic dermatitis and immunodeficiency. He has published over 400 peer reviewed articles and book chapters and is the editor of five books. He is involved in leadership roles in many professional organizations including President elect of the AAAAI.

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Allergy and Immunology, 1988 - 1990
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 1985 - 1988
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 1985
  • Kenyon College
    Kenyon CollegeB.A., Chemistry, 1977 - 1981

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1995 - 2025
  • KY State Medical License
    KY State Medical License 2002 - 2025
  • OH State Medical License
    OH State Medical License 1986 - 2025
  • IL State Medical License
    IL State Medical License 1988 - 1990
  • American Board of Allergy and Immunology Allergy & Immunology
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Top Doctor Cincinnati Magazine, 2000-2022
  • Distinguished Clinician Award AAAAI, 2019
  • Distinguished Clinician Award WAO, 2019
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema Attacks  
    Jonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA
  • Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients with Chronic Idiopathic (Spontaneous) Urticaria  
    Jonathan A Bernstein, Michael D Tharp, Ivo Abraham, JAMA
  • Correspondence and Reply Reply  
    Jonathan Bernstein, MD, ScienceDirect
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • 3rd Annual North American Rhinology & Allergy Conference(NARAC) 
    North American Rhinology & Allergy Conference(NARAC), Fajardo, Puerto Rico - 1/31/2013

Other

Press Mentions

  • Defining Treatment Success in Chronic Spontaneous Urticaria
    Defining Treatment Success in Chronic Spontaneous UrticariaNovember 7th, 2024
  • Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage Trial
    Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage TrialOctober 29th, 2024
  • Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
    Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible UrticariaOctober 26th, 2024
  • Join now to see all

Professional Memberships